Xoma

Agenus sells cut of Incyte, Merck milestone streams
Agenus sells cut of Incyte, Merck milestone streams
Fierce Biotech
Agenus
Incyte
Merck
Xoma
Flag link:
The 3 Best Biotech Stocks of 2017
The 3 Best Biotech Stocks of 2017
Motley Fool
biotech
Sangamo
Xoma
Marinus Pharma
Flag link:
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Endpoints
Novartis
Xoma
M&A
gevokizumab
cardiovascular disease
Flag link:
5 BioPharma Movers That Cannot Be Ignored
5 BioPharma Movers That Cannot Be Ignored
24/7 Wall St
MannKind
ZS Pharma
Xoma
Dyax
Valeant Pharmaceuticals
Flag link:
Novartis inks a string of deals to widen its immuno-oncology arsenal
Novartis inks a string of deals to widen its immuno-oncology arsenal
Fierce Biotech
Novartis
immuno-oncology
Admune Therapeutics
Xoma
Flag link:
Xoma enters exclusive license agreement with Novartis
Xoma enters exclusive license agreement with Novartis
Marketwatch
Xoma
Novartis
cancer
antibodies
Flag link:
10 Worst NASDAQ Biotech Stocks in the Third Quarter
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
Flag link:
Decimated by clinical failure, Xoma turns to plan B
Decimated by clinical failure, Xoma turns to plan B
Fierce Biotech
Xoma
clinical trials
gevokizumab
XOMA 358
endocrine disorders
Flag link:
Already with $1 billion in losses, Xoma plummets with late-stage drug failure
Already with $1 billion in losses, Xoma plummets with late-stage drug failure
Bizjournals.com
Xoma
gevokizumab
Behcet's uveitis
Flag link:
Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
TheStreet.com
Xoma
gevokizumab
Flag link:
3 Biotech Stocks 50% (or More) Off Their 5-Year Highs That Could Double
3 Biotech Stocks 50% (or More) Off Their 5-Year Highs That Could Double
Motley Fool
biotech
Xoma
Exelixis
Threshold Pharmaceuticals
Flag link:
3 Little-Known Biotech Stocks I'm Keeping an Eye On
3 Little-Known Biotech Stocks I'm Keeping an Eye On
Motley Fool
Neuralstem
Depomed
Xoma
Flag link:
3 Biotech Stocks With Upcoming Data That Could Be Huge
3 Biotech Stocks With Upcoming Data That Could Be Huge
24/7 Wall St
Aerie Pharma
Ocular Therapeutix
Xoma
gevokizumab
Rhopressa
OTX-TP
Flag link:
This Week in Biotech: Put It in Print
This Week in Biotech: Put It in Print
Motley Fool
Endo
Aveed
Rigel Pharmaceuticals
R118
Sangamo BioSciences
SB-728-T
NewLink Genetics
Xoma
gevokizumab
Flag link:
Xoma to stop testing drug as arthritis treatment
Xoma to stop testing drug as arthritis treatment
Yahoo/Reuters
Xoma
gevokizumab
osteoarthritis
Flag link:
Keep a Close Watch on Insys and XOMA Today
Keep a Close Watch on Insys and XOMA Today
Motley Fool
Xoma
Subsys
INSYS Therapeutics
Flag link:
XOMA completes enrollment in Phase 2 POC Gevokizumab trial
XOMA completes enrollment in Phase 2 POC Gevokizumab trial
Yahoo/Fly on the Wall
Xoma
gevokizumab
osteoarthritis
Flag link:
Symplmed Wins Rights from XOMA
Symplmed Wins Rights from XOMA
Yahoo/Zacks
Symplmed Pharmaceuticals
Xoma
Aceon
hypertension
Flag link:
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
TheStreet.com
Zerenex
Xoma
Vical
Takeda
sovaprevir
Soluble Ferric Pyrophosphate
Rockwell Medical
Orexigen
MM-398
Merrimack Pharmaceuticals
MannKind
Keryx
GTx
GSK
gevokizumab
enobosarm
Coronado Biosciences
Contrave
CNDO-201
clinical trials
ChemoCentryx
CCX140
Biodel
BIOD-123
Amigal
Amicus Therapeutics
Alnylam
ALN-TTR02
Allovectin
Afrezza
Achillion
ACH-3102
Flag link:
3 Humongous Health-Care Stocks This Week
3 Humongous Health-Care Stocks This Week
Motley Fool
Xoma
WebMD
Sequenom
Flag link:

Pages